SCHEDULE 13G/A: Stonepine Capital Entities Disclose 4.3% Stake in Aprea Therapeutics

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 4.3% beneficial ownership stake in Aprea Therapeutics, Inc., totaling 239,416 shares.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly reported beneficial ownership of 239,416 shares of Aprea Therapeutics, Inc. Common Stock.
• This ownership represents 4.3% of the outstanding Common Stock of Aprea Therapeutics, Inc.
• The total beneficial ownership includes 102,242 shares of Common Stock and 137,174 shares underlying warrants.
• The percentage is calculated based on 5,491,953 shares of Common Stock outstanding as of March 25, 2025, as reported in the Issuer's Form 10-K for the fiscal year ended December 31, 2024.
• The reporting persons have shared voting and shared dispositive power over all 239,416 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aprea Therapeutics, Inc.

Sentiment

Score: 5

Explanation: This is a factual ownership disclosure with no explicit positive or negative operational or financial news, indicating a neutral sentiment.

Positives

• The continued beneficial ownership by Stonepine Capital entities indicates ongoing investor interest in Aprea Therapeutics, Inc.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, which mitigates potential risks related to activist investor intentions.

Future Outlook

This document is an ownership disclosure and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a publicly traded company. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming their continued investment in the company.
• Management: Awareness of a substantial shareholder, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Aprea Therapeutics, Stonepine Capital Management, Stonepine Capital, Jon M. Plexico, Schedule 13G, beneficial ownership, common stock, SEC filing, investment, warrants